A Dose of Zoledronate Maintains Bone Mineral Density in Osteoporosis
In This Article
- A study presented at the American Society for Bone and Mineral Research (ASBMR) annual meeting found that a single dose of zoledronate could preserve bone mineral density gains in postmenopausal women with osteoporosis
- Sabashini Ramchand, MBBS, author of the study, said that certain treatment plans including zoledronic acid could be useful in the long-term management of osteoporotic related fractures
Subscribe to the latest updates from Rheumatology, Allergy and Immunology Advances in Motion
It remains unclear what the best method is for the prevention of bone loss after stopping denosumab. A previous trial, called the DATA-HD trial, found that teriparatide combined with denosumab increased bone mineral density at all anatomic sites.
The DATA-HD extension trial, presented at the American Society for Bone and Mineral Research (ASBMR) annual meeting by Sabashini Ramchand, MBBS, research fellow in the Endocrine Unit at Massachusetts General Hospital, found that a single dose of zoledronate may be an effective strategy in the long-term management of high-risk osteoporotic fractures.
Reported on Rheumatology Network, the researchers found that a single dose of zoledronate maintains the increase in the femoral neck and total hip bone mineral density achieved with a combination of teriparatide/denosumab at both 12 and 27 months among postmenopausal women with osteoporosis. At the spine, bone mineral density was maintained for 12 months after zoledronate administration, then decreased after 27 months, but still remained higher than the baseline in the previous trial.
Another follow up trial, DATA-HD Extension HR-pQCT, also found that zoledronate maintained trabecular, but not cortical, bone mineral density and microarchitecture at peripheral anatomic sites after treatment with teriparatide and denosumab.
Dr. Ramchand suggests that the increase in cortical porosity after 12 months, and the ongoing microstructural deterioration observed, may mean re-dosing of zoledronic acid is required.
Read More on Rheumatology Network
Learn more about the Rheumatology Unit at Mass General
Refer a patient to Division of Rheumatology at Mass General